姓名：王育生性别：女政治面貌：中共党员学历：硕士研究生学位：博士研究生职称：主任医师

博、硕导师：博士生导师本岗位工作年数：5年

研究方向：消化道肿瘤发病及耐药机制研究

荣誉称号：百千万卫生人才培养工程骨干精英人才

学术任职：

中国临床肿瘤学会(CSCO)理事

国家肿瘤质控中心胃癌质控专家委员会委员

中国研究型医院学会肿瘤学专委会常委

北京癌症防治学会食管癌专委会常委

CSCO胰腺癌专委会、 胃肠间质瘤专委会、临床研究专委会委员

CACA整合肿瘤肾脏病专委会、食管肿瘤整合康复专委会常委

CACA肿瘤肝脏病学专委会、MDT专委会、信息化管理专委会 委员

山西省抗癌协会肿瘤异质性与个体化治疗委员会主任委员

山西省老年医学学会肿瘤整合医学分会会长

山西省医师协会肝病医师分会肝癌学组组长

山西省抗癌协会肿瘤临床试验专委会、食管癌专委会、肿瘤胃肠病学专委会、肿瘤整体评估专委会副主任委员

山西省医师协会肝病医师分会青委会副主任委员

山西省健康管理学会健康教育专委会副主任委员

山西省老年医学学会胃肠间质瘤分会 、 临床营养分会副会长

近五年承担科研课题情况：

(1)山西省卫健委,“四个一批”科技兴医创新计划项目重点攻关项目, 2023XM024, KRAS分子分型指导下的晚期胰腺癌精准诊疗方案研究与验证, 2023-09至2025-08, 15万元,在研,主持

(2)北京科创基金项目,基础研究, KC2021-JX-0186-104,通过阻断PD- 1/PD-L1和P38MAPK双通路达到抗MSS型结肠癌细胞增殖的研究, 2022-06至2024-06, 15万元,结题,主持

(3)山西省卫健委,基础研究, 2022025,阻断P38MAPK信号通路逆转胃癌治疗中PD-1抑制剂耐药的机制研究, 2022-01至2024-01, 3万元,结题,主持

代表性论著及近五年的代表性论文（限10项以内）：

1、Meng Qianhao^1†, Zhao Jian^2†, Yu Yuanyuan^1†, Wang Ke¹, Ren Jing¹,Xu Chang¹,Wang Yusheng^2*and Wang Guangyu^1*,Survival comparison of first-line treatment regimens in patients with braf-mutated advanced colorectal cancer: a multicenter retrospective study [J]. BMC Cancer, 2023, 23(1): 191.

2、Zhu Xiao-Dong^1,2,†,Huang Ming-Zhu^1,2,†,Wang Yu-Sheng^3,†,Feng Wan-Jing^1,2,†,Chen Zhi-Yu^1,2,†,He Yi-Fu^4,†,Zhang Xiao-Wei^1,2,Liu Xin^1,2,Wang Chen-Chen^1,2,Zhang Wen^1,2,Ying Jie-Er⁵,Wu Jun⁶,Yang Lei⁷,Qin Yan-Ru⁸,Luo Jian-Feng⁹,Zhao Xiao-Ying^1,2,Li Wen-Hua^1,2,Zhang Zhe^1,2,Qiu Li-Xin^1,2,Geng Qi-Rong^1,2,Zou Jian-Ling^1,2,Zhang Jie-Yun^1,2,Zheng Hong¹⁰,Song Xue-Feng³,Wu Shu-Sheng⁴,Zhang Cheng-Yan³,Gong Zhe^1,2,Liu Qin-Qin^1,2,Wang Xiao-Feng⁸,Xu Qi⁵,Wang Qi⁶,Ji Jian-Mei⁷,Zhao Jian³,Guo Wei-Jian^1,2,XELOX doublet regimen versus EOX triplet regimen as first-line treatment for advanced gastric cancer: An open-labeled, multicenter, randomized, prospective phase III trial (EXELOX) [J]. Cancer Commun (Lond), 2022, 42(4): 314-326.

3、Zhang Ninggang^1†, Ren Yaqiong^2†, Zan Likun³, Zhang Xuting⁴, Jian Zhao¹, Wen Lu¹andWang Yusheng^1*,Case report: Kidney perivascular epithelioid cell tumor treated with anti-VEGFR tyrosine kinase inhibitor and MTOR inhibitor [J]. Front Oncol, 2022, 12:966818.

4、Tian Zhihui, Zhao Jian,Wang Yusheng,The prognostic value of TPM1-4 in hepatocellular carcinoma [J]. Cancer Med, 2022, 11(2): 433-446.

5、Rong Xuetong¹, Liu Haiyi², Yu Hongmei¹, Zhao Jian²,Wang Jie¹,Wang Yusheng²,Efficacy of apatinib combined with FOLFIRI in the first-line treatment of patients with metastatic colorectal cancer [J]. Invest New Drugs, 2022, 40(2): 340-348.

6、Yu Penngfei,^a,†Wang Yusheng,^b,†Yu Yanfei,^cWang aodi,^cHuang Ling ,^aZhang Yuan ,^cLiu Wenjing,^cWu Haiyan,^cYao Ming ,^cDu Yi-an ,^aCheng Xiangdong^a,Deep Targeted Sequencing and Its Potential Implication for Cancer Therapy in Chinese Patients with Gastric Adenocarcinoma [J]. Oncologist, 2021, 26(5): e756-e768.

7、Wang Yusheng,¹Shang Kun,¹Zhang Ninggang,²Zhao Jian,²and Cao Bangwei^1,i,Tumor-Associated Macrophage-Derived Exosomes Promote the Progression of Gastric Cancer by Regulating the P38MAPK Signaling Pathway and the Immune Checkpoint PD-L1 [J]. Cancer Biother Radiopharm, 2021: Oct 25.

8、Wang Yusheng^1,2, Zhao Jian², Yu Hongmei³, Wang Jie⁴, Zhang Ninggang², Cao Bangwei¹,Efficacy and safety of sintilimab-based regimens against advanced gastric and gastroesophageal junction adenocarcinoma [J]. J Cancer Res Ther, 2021, 17(5): 1234-1240.

9、Wang Jie,¹Xi Yanfeng,²Zhao Jian,³Rong Xuetong,¹Lu Weidong,¹andWang Yusheng³,The Clinicopathological Characteristics and Prognoses of dMMR Gastric Adenocarcinoma Patients [J]. Gastroenterol Res Pract, 2021, 2021: 4269781.

10、Huang Mingzhu^1,2,Yang Yue^1,2,Zhu Xiaodong^1,2,Chen Zhiyu^1,2,Zhang Wen^1,2,Wang Chenchen^1,2,Zhang Xiaowei^1,2,Qiu Lixin^1,2,Zhang Zhe^1,2,Zhao Xiaoying^1,2,Li Wenhua^1,2,Wang Yusheng³,Guo Weijian^1,2,A prospective phase II study of raltitrexed combined with S-1 as salvage treatment for patients with refractory metastatic colorectal cancer[J]. Asia Pac J Clin Oncol, 2021, 17(6): 513-521.